---
title: "Ulixacaltamide in Essential tremor: Clinical evidence"
description: "Formulary evidence on Ulixacaltamide in Essential tremor: Clinical evidence. Covers Essential3 study 1, Essential3 study 2, Essential1, PRAX-944-221, and PRAX-944-105. 114 evidence topics quoted from 24 sources."
canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ulixacaltamide in Essential tremor: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Essential3 Study 1

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Efficacy, safety, and tolerability versus placebo

> “Evaluating the efficacy, safety, and tolerability of ulixacaltamide vs. placebo in adults with essential tremor (ET)”

Source: [Brillman et al. (2026b)](https://www.aan.com/msa/public/events/abstractdetails/63690)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study country

> “conducted within the United States”

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.1.2-2"></a>

###### Reported program initiation

> “In November 2023, Praxis initiated Essential3, the Phase 3 program for ulixacaltamide.”

Source: [Praxis Precision Medicines third quarter 2023 results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-10)

<a id="topic-3.1.1.2-3"></a>

###### Primary results announcement

> “October 16, 2025”

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.1.2-4"></a>

###### Exact first-participant and last-participant visit dates

No evidence found.

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized parallel-group design

> “Randomized, double-blind, placebo-controlled”

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.3-2"></a>

###### Original planned treatment duration

> “Essential3, the Phase 3 program for ulixacaltamide, comprises two simultaneous Phase 3 studies including a 12-week, parallel design study and 12-week randomized withdrawal study for stable responders.”

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-3.1.1.3-3"></a>

###### Randomization and treatment schedule

| Design feature | Reported value |
| --- | --- |
| Ulixacaltamide-to-placebo randomization | “1:1” |
| Titration period | “2-week” |
| Randomized treatment period | “12 weeks” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Original age and primidone criteria

> “age of 18 and 85 years (inclusive)”
> “Unwillingness or inability to discontinue primidone”

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-3.1.1.4-2"></a>

###### Disease duration and stable background treatment

| Criterion | Reported requirement |
| --- | --- |
| Essential tremor symptom duration | “≥3 years” |
| Stable background medication before screening | “≥28 days” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.4-3"></a>

###### Prescreening survey population, distinct from enrolled participants

> “Data are presented for 75,000 survey responders as of 08/2024.”

Source: [Able et al. (2025b)](https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-005726.html)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Investigational regimen

| Treatment attribute | Reported value |
| --- | --- |
| Ulixacaltamide maintenance dose | “60 mg QD” |
| Initial titration | “2-week” |
| Comparator | “placebo” |
| Treatment duration | “12 weeks” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using mADL11 as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Instrument composition and meaningful within-participant change

> “comprising TETRAS-ADL items, excluding social impact, individually scored from 0-3”
> “An MSD was consistently defined as ≥2 points”

Source: [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf)

<a id="topic-3.1.1.6.1-2"></a>

###### Original primary endpoint timing

> “mADL11 change from baseline to Day 84”

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Primary endpoint in the final results presentation

| Endpoint component | Reported value |
| --- | --- |
| Instrument | “mADL11” |
| Primary assessment | “Day 56” |
| Additional treatment-period assessment | “Day 84” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.6.1-4"></a>

###### Variability of performance-based tremor measurements

> “Tremor is not constant: a single brief sample of a fluctuating signal cannot capture disability”

Source: [Petrou (2026)](https://praxismedicines.com/aan2026-s11-004/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Original planned enrollment

| Study component | Planned participants |
| --- | --- |
| Study 1 parallel design | “400” |

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### Actual enrollment and analysis populations

| Population | Ulixacaltamide | Placebo |
| --- | --- | --- |
| Enrolled and ITT | “236 (100%)” | “237 (100%)” |
| Safety | “233 (98.7%)” | “234 (98.7%)” |
| mITT | “199 (84.3%)” | “233 (98.3%)” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### mITT eligibility after randomization

> “received ≥1 dose of study drug and had ≥1 post-baseline efficacy assessment.”

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.7.2-2"></a>

###### Interim futility recommendation and continuation

> “the IDMC has recommended that the study be stopped for futility”
> “Praxis has decided to continue both studies to completion”

Source: [Praxis Precision Medicines Essential3 update announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-update-essential3-and)

<a id="topic-3.1.1.7.2-3"></a>

###### Missing-data sensitivity analysis

| Analysis parameter | Reported value |
| --- | --- |
| Tipping-point penalty | “2.5 points” |
| Estimated treatment difference and 95% CI | “-1.63 (-2.70, -0.57)” |
| Probability value | “p=0.0026” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.7.2-4"></a>

###### Complete statistical analysis plan and multiplicity procedures

No evidence found.

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Study discontinuation in the safety population

| Disposition | Ulixacaltamide, 233 participants | Placebo, 234 participants |
| --- | --- | --- |
| Discontinued from the study | “83 (35.6%)” | “13 (5.6%)” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic and clinical characteristics of the mITT population

| Characteristic | Ulixacaltamide, 199 participants | Placebo, 233 participants |
| --- | --- | --- |
| Age, mean years and SD | “67.9 (9.1)” | “68.9 (8.1)” |
| Male and female percentages | “57.3% / 42.7%” | “56.7% / 43.3%” |
| White and other race percentages | “98.5% / 1.5%” | “95.7% / 4.3%” |
| Years since essential tremor onset, mean and median | “29.8 (26.0)” | “31.1 (27.0)” |
| Currently receiving essential tremor medication | “44.2%” | “48.1%” |
| Currently receiving propranolol | “35.7%” | “36.5%” |
| mADL11, mean and SD | “18.5 (2.4)” | “18.4 (2.4)” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: mADL11 change from baseline to Day 56

| “ULIXACALTAMIDE (N = 199)” | “PLACEBO (N= 233)” |
| ------------------------ | ----------------- |
| “-4.3” | “-1.7” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

> “PRIMARY ENDPOINT”
> “Ulixacaltamide demonstrated a statistically significant clinical improvement of -2.57 points in the primary endpoint, mADL11 change at Day 56 vs. placebo (95% CI, -3.62 to -1.53; p=0.0000014).”

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary endpoint probability value in the results presentation

> “Ulixacaltamide demonstrated a statistically significant clinical improvement of -2.57 points in the primary endpoint, mADL11 change at Day 56 vs. placebo (95% CI, -3.62 to -1.53; p=0.0000014).”

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.8.3-3"></a>

###### Change over time

| Outcome | Least-squares mean difference versus placebo and 95% CI | Probability value |
| --- | --- | --- |
| Rate of disease improvement | “-2.27 (-3.11, -1.42)” | “<0.0001” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.8.3-4"></a>

###### Day 84 sensitivity analysis

| Outcome | Ulixacaltamide | Placebo | Probability value |
| --- | --- | --- | --- |
| mADL11 change from baseline to Day 84 | “-3.4” | “-1.9” | “0.0049” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

Additional sources: [Brillman et al. (2026c)](https://www.neurology.org/doi/abs/10.1212/WNL.0000000000217731)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### Patient and clinician global impressions

| Outcome | Least-squares mean difference versus placebo and 95% CI | Probability value |
| --- | --- | --- |
| PGI-C at Day 56 | “-0.60 (-0.81, -0.39)” | “<0.0001” |
| CGI-S change at Day 56 | “-0.29 (-0.46, -0.12)” | “0.0007” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.8.4-2"></a>

###### Generic health utility and preference-based quality-of-life outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Drug-related TEAEs leading to discontinuation

| “STUDY 1” · “ULIXACALTAMIDE” · “(N=233)” | “STUDY 1” · “PLACEBO” · “(N=234)” |
| ---------------------------------------- | --------------------------------- |
| “63 (27.0%)” | “4 (1.7%)” |

Source: [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/)

<a id="topic-3.1.1.8.5-2"></a>

###### Overall and serious adverse events

| Safety outcome | Ulixacaltamide, 233 participants | Placebo, 234 participants |
| --- | --- | --- |
| Any TEAE | “221 (94.9%)” | “177 (75.6%)” |
| Severe TEAE | “14 (6.0%)” | “10 (4.3%)” |
| Any serious adverse event | “2 (0.9%)” | “8 (3.4%)” |

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/)

<a id="topic-3.1.1.8.5-3"></a>

###### Common adverse events and serious treatment-related events across the Essential3 program

> “The most common (≥10% patients) treatment emergent adverse events (TEAs) were constipation, dizziness, euphoric mood, brain fog, headache, paraesthesia and insomnia.”
> “There were no deaths and no drug-related serious adverse events.”

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The mITT analysis included 199 of 236 participants assigned ulixacaltamide and 233 of 237 assigned placebo. Study discontinuation was 35.6% versus 5.6% in the safety populations. These imbalances warrant consideration alongside the reported missing-data sensitivity analysis. The original design specified a Day 84 primary assessment, whereas the final report used Day 56; the Day 84 sensitivity result also favored ulixacaltamide. The IDMC had recommended stopping for futility before the sponsor continued the studies. Treatment lasted 12 weeks, the comparator was placebo, and more than 95% of each mITT group was White, limiting conclusions about longer-term comparative effectiveness and other populations.

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/); [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf); [Praxis Precision Medicines Essential3 update announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-update-essential3-and); [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="heading-3.1.2"></a>

#### 3.1.2 Essential3 Study 2

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Maintenance of response and durability

> “Assessing maintenance of response and durability of effect of ulixacaltamide in essential tremor (ET)”

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study country

> “conducted within the United States”

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.2.2-2"></a>

###### Reported initiation of the shared Essential3 program

| Milestone | Reported date |
| --- | --- |
| Program initiation | “November 2023” |

Source: [Praxis Precision Medicines third quarter 2023 results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-10)

<a id="topic-3.1.2.2-3"></a>

###### Exact first-participant and last-participant visit dates

No evidence found.

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Blinded lead-in followed by randomized withdrawal

> “BLINDED LEAD-IN: 8 WEEKS”
> “RW PHASE: 4 WEEKS”

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="topic-3.1.2.3-2"></a>

###### Randomization of qualifying responders

| Design feature | Reported value |
| --- | --- |
| Continued ulixacaltamide versus withdrawal to placebo | “1:1” |
| Randomized-withdrawal duration | “4 weeks” |

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Adult essential tremor population

| Criterion | Reported requirement |
| --- | --- |
| Age | “18–85 years” |
| Symptom duration | “≥3 years” |
| Stable background medication before screening | “≥28 days” |

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

<a id="topic-3.1.2.4-2"></a>

###### Response required for randomized withdrawal

| Criterion | Reported threshold or assessment |
| --- | --- |
| mADL11 reduction for stable response | “3 points” |
| Visits averaged for response qualification | “Day 49 and 56” |
| Consecutive visits required to establish loss of response | “2 consecutive visits” |
| Deterioration from randomized-withdrawal baseline | “3 points or more” |

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Ulixacaltamide lead-in regimen

> “ulixacaltamide hydrochloride 60mg QD (after 2-week titration)”

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

<a id="topic-3.1.2.5-2"></a>

###### Randomized-withdrawal treatment groups

| Randomized group | Participants |
| --- | --- |
| Continued ulixacaltamide | “N = 40” |
| Placebo | “N = 40” |

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using mADL11 Response Maintenance as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary response-maintenance outcome

> “The proportion of participants that maintain response”

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="topic-3.1.2.6.1-2"></a>

###### Functional relevance of the underlying scale

> “comprising TETRAS-ADL items, excluding social impact, individually scored from 0-3”
> “An MSD was consistently defined as ≥2 points”

Source: [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Original planned enrollment

| Study component | Planned participants |
| --- | --- |
| Study 2 randomized-withdrawal design | “200” |

Source: [Able et al. (2024b)](https://praxismedicines.com/wp-content/uploads/2024/09/MDS2024_E3_StudyDesign_Poster_QRcode.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Actual enrollment

| Population | Reported participants |
| --- | --- |
| Enrolled | “238” |

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html)

<a id="topic-3.1.2.7.1-3"></a>

###### Stable responders entering randomized withdrawal

| Population | Reported participants |
| --- | --- |
| Qualifying stable responders randomized | “N = 80” |
| Continued ulixacaltamide | “N = 40” |
| Placebo | “N = 40” |

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Randomized-withdrawal mITT population

| Analysis population | Ulixacaltamide | Placebo |
| --- | --- | --- |
| Randomized-withdrawal mITT | “n=40” | “n=40” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.2.7.2-2"></a>

###### Additional model specifications and missing-data procedures

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Overall study discontinuation

| Disposition | Ulixacaltamide, 231 participants in the safety population |
| --- | --- |
| Discontinued from the study | “88 (38.1%)” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.2.8.1-2"></a>

###### Disposition separately within each randomized-withdrawal treatment group

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics separately for the randomized-withdrawal treatment groups

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Maintenance of response during randomized withdrawal

| “Ulixacaltamide, N = 40” | “Placebo , N = 40” |
| ----------------------- | ---------------- |
| “55%” | “33%” |

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

> “p=0.037”
> “OR=2.7”
> “(1.06-6.92)”

Source: [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/)

<a id="topic-3.1.2.8.3-2"></a>

###### Rate of change during randomized withdrawal

| Outcome | Ulixacaltamide | Placebo | Probability value |
| --- | --- | --- | --- |
| Rate of disease improvement from randomized-withdrawal baseline to Day 84 | “2.8” | “5.2” | “0.004” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Patient and clinician global impressions during randomized withdrawal

| Outcome | Ulixacaltamide | Placebo | Probability value |
| --- | --- | --- | --- |
| PGI-C at Day 84 | “3.24” | “3.67” | “0.087” |
| CGI-S change from Day 56 to Day 84 | “0.39” | “0.73” | “0.055” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.2.8.4-2"></a>

###### Generic health utility and preference-based quality-of-life outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Drug-related TEAEs leading to discontinuation

| “STUDY 2” · “ULIXACALTAMIDE” · “(N=231)” |
| ---------------------------------------- |
| “65 (28.1%)” |

Source: [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/)

<a id="topic-3.1.2.8.5-2"></a>

###### Overall safety population

| Safety outcome | Ulixacaltamide, 231 participants |
| --- | --- |
| Any TEAE | “209 (90.5%)” |
| Severe TEAE | “17 (7.4%)” |
| Any serious adverse event | “4 (1.73%)” |

Source: [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="topic-3.1.2.8.5-3"></a>

###### Safety separately within each randomized-withdrawal treatment group

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The randomized comparison included 80 selected responders from 238 enrolled participants and assessed withdrawal over four weeks. Its response-maintenance estimate therefore applies to participants who reached the response threshold after initial treatment, rather than all adults starting ulixacaltamide. The safety population included 231 participants; drug-related adverse events led to discontinuation in 28.1%. PGI-C and CGI-S comparisons during withdrawal did not reach statistical significance, with p-values of 0.087 and 0.055. The reported overall safety results should not be interpreted as adverse-event comparisons between the two randomized-withdrawal groups.

Source: [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html); [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/); [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/); [Praxis Precision Medicines Essential3 topline results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1)

<a id="heading-3.1.3"></a>

#### 3.1.3 Essential1

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Efficacy, safety, and tolerability in essential tremor

> “evaluating the efficacy, safety and tolerability of ulixacaltamide (PRAX-944)”

Source: [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Reported study initiation

> “Praxis initiated the PRAX-944 Phase 2b Essential1 Study for treatment of ET in the third quarter of 2021”

Source: [Praxis Precision Medicines (2021)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-provides-corporate-update-and-2)

<a id="topic-3.1.3.2-2"></a>

###### Study locations and exact completion date

No evidence found.

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Randomized placebo-controlled study

> “Multi-center, randomized, double-blinded, placebo-controlled”

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.3-2"></a>

###### Allocation and follow-up

| Design feature | Reported value |
| --- | --- |
| Allocation among two active regimens and placebo | “1:1:1” |
| Intervention period | “56 days” |
| Safety follow-up | “14 days” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.3-3"></a>

###### Extension and randomized-withdrawal substudy design

| Design component | Reported value |
| --- | --- |
| Extension efficacy assessment | “14 weeks” |
| Randomized-withdrawal substudy participants | “21” |
| Initial ulixacaltamide assignment in the substudy | “11” |
| Initial placebo assignment in the substudy | “10” |
| Initial randomized-withdrawal period before crossover | “the initial 3-week period, crossing over to either placebo or ulixacaltamide for an additional 3-week period” |

Source: [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Disease duration and functional severity

| Criterion | Reported requirement |
| --- | --- |
| Duration of clinical essential tremor diagnosis | “≥3 YEARS” |
| Functional impairment | “MODERATE TO SEVERE” |
| Instruments used to determine functional impairment | “TETRAS AND CGI-S” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Randomized dose regimens and duration

> “60 mg or 100 mg”
> “56 days”

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.5-2"></a>

###### Background propranolol

> “a stable dose of propranolol for the duration of the study.”

Source: [Able (2024a)](https://praxismedicines.com/wp-content/uploads/2024/04/AAN2024_Propranolol_Talk_QRcode.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Modified TETRAS Activities of Daily Living as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary scale and subsequent mADL11 analysis

| Outcome component | Reported measure or value |
| --- | --- |
| Primary assessment | “Day 56” |
| Primary scale | “mADL” |
| Maximum primary scale score | “42” |
| Performance components included in the primary scale | “Spirals (left, right)” |
| Additional performance component | “Handwriting” |
| Post-hoc functional analysis | “mADL excluding TETRAS-PS items” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.6.1-2"></a>

###### Meaningful change in the functional-only mADL11 scale

> “comprising TETRAS-ADL items, excluding social impact, individually scored from 0-3”
> “An MSD was consistently defined as ≥2 points”

Source: [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf)

<a id="topic-3.1.3.6.1-3"></a>

###### Reliability of the TETRAS performance scale

> “The inter- and intra-rater intraclass correlations for head and upper limb tremor ranged from 0.86 to 0.96”

Source: [Elble et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4157921/)

<a id="topic-3.1.3.6.1-4"></a>

###### Separate validation of the TETRAS-PRO instrument

> “The 30-day estimate of minimum detectable change (MDC) was 6.6 (95%CI 5.2–8.0).”

Source: [Shih et al. (2024)](https://tremorjournal.org/articles/10.5334/tohm.886)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Randomized and analyzed participants

> “132 adults were randomized and treated; 116 were included in mITT analysis”

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Treatment-specific analysis populations

| Population | Pooled ulixacaltamide regimens | Placebo |
| --- | --- | --- |
| Safety | “n=91” | “n=41” |
| mITT | “n=78” | “n=38” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.7.1-3"></a>

###### Extension completer populations

| Population | Reported participants |
| --- | --- |
| Continued into the blinded lead-in extension | “75” |
| Included in the extension completer analysis | “65” |
| Continued ulixacaltamide | “n=39” |
| Delayed initiation of ulixacaltamide after placebo | “n=26” |

Source: [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Summary

The reported mITT population comprised 116 participants who met the protocol version 4 eligibility requirements and received study treatment. Sixteen treated participants from an earlier protocol version were excluded from this analysis. Active-dose groups were pooled in the reported efficacy comparisons. The repeated-measures model adjusted for baseline value, propranolol use, and family history of essential tremor. The poster identifies the reported p-values as nominal.

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Repeated-measures analysis

> “Mixed Model Repeated Measures (MMRM), Adjusted by baseline value, propranolol use, and familial history of ET. All p values are nominal.”

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Discontinuation within the mITT population

| Disposition | Ulixacaltamide, 78 participants | Placebo, 38 participants |
| --- | --- | --- |
| Discontinued | “13 (17%)” | “4 (11%)” |
| Discontinued because of adverse events | “9 (12%)” | “1 (3%)” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographic and clinical characteristics of the mITT population

| Characteristic | Ulixacaltamide, 78 participants | Placebo, 38 participants |
| --- | --- | --- |
| Age, mean and range | “70.4 (32, 86)” | “67.7 (29, 88)” |
| Family history of essential tremor | “59 (76%)” | “23 (61%)” |
| Propranolol use | “27 (35%)” | “9 (24%)” |
| Duration of essential tremor, mean years | “20.3” | “20.2” |
| mADL score, mean and range | “20.6 (12, 32)” | “20.8 (12, 34)” |
| TETRAS-ADL score, mean and range | “29.0 (20, 38)” | “28.6 (19, 39)” |
| mADL11 score, mean and range | “16.4 (9, 25)” | “16.4 (8, 25)” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary and secondary endpoint interpretation in the initial results announcement

> “primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126)”
> “nominal statistical significance in TETRAS-ADL secondary endpoint (p=0.026)”

Source: [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1)

<a id="topic-3.1.3.8.3-2"></a>

###### Day 56 least-squares mean changes

| Outcome | Ulixacaltamide | Placebo | Reported probability value |
| --- | --- | --- | --- |
| mADL primary endpoint | “-3.01” | “-1.44” | “p = 0.126” |
| mADL excluding performance items, post-hoc analysis | “-2.69” | “-0.88” | “p = 0.042” |
| TETRAS-ADL secondary endpoint | “-3.6” | “-1.07” | “p = 0.026” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### Extension and randomized-withdrawal findings

> “up to 14 weeks showed maintained or improved efficacy results”
> “Patients withdrawing from ulixacaltamide to placebo experienced worsening in mADL11”

Source: [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)

<a id="topic-3.1.3.8.3-4"></a>

###### Extension completer analysis: mean mADL11 improvement

| Treatment sequence | Week 8 improvement | Week 14 improvement |
| --- | --- | --- |
| Continued ulixacaltamide | “3.09” | “4.81” |
| Placebo followed by ulixacaltamide | “1.21” | “4.36” |

Source: [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Global impression outcomes

> “Nominal statistically significant improvements observed in Clinical Global Impression-Severity (CGI-S) and in Patient Global Impression-Change (PGI-C)”

Source: [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1)

<a id="topic-3.1.3.8.4-2"></a>

###### Generic health utility and preference-based quality-of-life outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Treatment-emergent adverse events

| Safety outcome | Ulixacaltamide, 91 participants | Placebo, 41 participants |
| --- | --- | --- |
| Any TEAE | “70 (76.9%)” | “21 (51.2%)” |
| Dizziness | “13 (14.3%)” | “2 (4.9%)” |
| Constipation | “9 (9.9%)” | “0” |
| Headache | “8 (8.8%)” | “1 (2.4%)” |
| Fatigue | “8 (8.8%)” | “1 (2.4%)” |
| Anxiety | “6 (6.6%)” | “0” |
| Feeling abnormal | “6 (6.6%)” | “0” |
| Paraesthesia | “6 (6.6%)” | “0” |

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The primary mADL endpoint did not reach statistical significance. Secondary endpoint p-values were nominal, and the functional-only mADL analysis was post hoc. The mITT analysis excluded 16 of 132 treated participants based on protocol-version eligibility and pooled the active-dose regimens. The randomized treatment period lasted eight weeks. Extension results were based on 65 completers, and the randomized-withdrawal substudy included 21 participants. These analyses provide supporting information but do not replace the unsuccessful primary comparison or establish long-term comparative effectiveness.

Source: [Giroux et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2023/09/Able_IAPRD2023_E1_Readout.pdf); [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1); [Giroux et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/Giroux_MDS2023_E1_MSD_SUBMIT.pdf); [Praxis Precision Medicines Essential1 randomized withdrawal results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-data-randomized)

<a id="heading-3.1.4"></a>

#### 3.1.4 PRAX-944-221

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Clinical and pharmacokinetic evaluation

> “evaluating efficacy, safety, tolerability, and pharmacokinetics of PRAX-944 in adults with essential tremor (ET).”

Source: [Olhaye et al. (2022b)](https://www.mdsabstracts.org/abstract/a-phase-2-clinical-trial-evaluating-the-efficacy-safety-tolerability-and-pharmacokinetics-of-prax-944-in-adults-with-essential-tremor/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study locations and exact conduct dates

No evidence found.

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Part A open-label design

> “Part A: Open label”

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="topic-3.1.4.3-2"></a>

###### Part B lead-in and withdrawal periods

| Design feature | Reported value |
| --- | --- |
| Open-label phase | “42-day” |
| Randomized-withdrawal phase | “14-day” |
| Withdrawal-phase masking and control | “randomized, double-blind, placebo-controlled” |

Source: [Olhaye et al. (2022b)](https://www.mdsabstracts.org/abstract/a-phase-2-clinical-trial-evaluating-the-efficacy-safety-tolerability-and-pharmacokinetics-of-prax-944-in-adults-with-essential-tremor/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Adult population and background treatment

> “adult patients (≥18 years) with ET.”
> “Eligible participants were receiving either no medications or 1 stable dose tremor medication, excluding primidone.”

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dose-escalation regimens

| Treatment component | Reported regimen |
| --- | --- |
| Part A initial dose | “20 mg” |
| Part A subsequent dose | “40 mg” |
| Duration at each Part A dose | “7 days” |
| Highest Part B dose | “120 mg” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using TETRAS Upper Limb Score as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary outcomes by study part

| Study part | Primary outcome |
| --- | --- |
| Part A | “upper limb tremor” |
| Part B | “safety and tolerability” |

Source: [Olhaye et al. (2022b)](https://www.mdsabstracts.org/abstract/a-phase-2-clinical-trial-evaluating-the-efficacy-safety-tolerability-and-pharmacokinetics-of-prax-944-in-adults-with-essential-tremor/)

<a id="topic-3.1.4.6.1-2"></a>

###### Reliability of head and upper-limb tremor assessments

> “The inter- and intra-rater intraclass correlations for head and upper limb tremor ranged from 0.86 to 0.96”

Source: [Elble et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4157921/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Convenience-sample planning

> “was not selected according to any statistical power calculation.”

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Planned sample size

| Population | Planned participants |
| --- | --- |
| Each study part | “up to 12 participants” |
| Permitted expansion of Part B | “up to 24 participants” |

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-3.1.4.7.1-3"></a>

###### Part A efficacy population

> “Change from baseline in TETRAS score (N=6)”

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Summary

The protocol defined the safety population by receipt of at least one dose. The full analysis population additionally required valid baseline and post-baseline TETRAS assessments. The pharmacokinetic population required at least one evaluable plasma concentration. Analyses were primarily descriptive and separated the study parts; the randomized portion of Part B was summarized by assigned continuation treatment. The sample size was selected for feasibility rather than a formal confirmatory power calculation.

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Safety analysis population

> “all participants who received at least 1 dose of study drug.”

Source: [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Part A disposition

| Disposition | Reported participants |
| --- | --- |
| Received PRAX-944 | “Seven” |
| Completed all study visits | “6” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="topic-3.1.4.8.1-2"></a>

###### Part B evaluable and completion populations

| Population | Reported participants |
| --- | --- |
| Evaluable participants | “14” |
| Completed open-label and randomized-withdrawal phases | “Eleven” |
| Ulixacaltamide among completers | “6” |
| Placebo among completers | “5” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Part A baseline severity and propranolol use

| Characteristic | Reported value |
| --- | --- |
| Mean baseline TETRAS-UL score | “12.4” |
| Baseline TETRAS-UL range | “10-15” |
| Concomitant propranolol among efficacy participants | “Five (83%)” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Part A upper-limb tremor change at Day 14

> “TETRAS-UL decrease of 2.8 points from baseline on Day 14”
> “42% reduction in upper limb tremor amplitude”

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="topic-3.1.4.8.3-2"></a>

###### Part B instrument-measured tremor during randomized withdrawal

| Outcome | Continued PRAX-944 | Placebo |
| --- | --- | --- |
| Kinesia One mean percentage change from Day 42 | “3%” | “29%” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

###### Part B functional change during randomized withdrawal

| Outcome | Continued PRAX-944 | Placebo |
| --- | --- | --- |
| Modified ADL mean percentage change from Day 42 | “8%” | “139%” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="topic-3.1.4.8.4-2"></a>

###### Disease-specific quality-of-life questionnaire results

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Part B dose completion and tolerability

| Safety or exposure outcome | Reported value |
| --- | --- |
| Participants completing titration at the highest dose | “Eight of 11” |
| Highest dose | “120 mg” |
| Evaluable participants discontinuing because of TEAEs | “three of 14” |
| Discontinuation unrelated to study drug | “1” |

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

Part A was open label, with seven treated participants and six completing all visits. Five of the six efficacy participants were receiving propranolol. Part B reported 14 evaluable participants and 11 completing the open-label and randomized-withdrawal phases. These small populations, the uncontrolled initial treatment periods, and the brief withdrawal comparison limit precision and generalizability. The protocol describes feasibility-based sampling and primarily descriptive analyses. The findings support dose and endpoint development but do not independently establish confirmatory efficacy or long-term safety.

Source: [Olhaye et al. (2022a)](https://praxismedicines.com/wp-content/uploads/2023/09/Olhaye-et-al_MDS2022_944-221_Abstract-951_QRcode.pdf); [ClinicalTrials.gov NCT05021978](https://cdn.clinicaltrials.gov/large-docs/78/NCT05021978/Prot_000.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 PRAX-944-105

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Safety and clinical pharmacology

> “safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) parameters”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Location and conduct dates

> “Melbourne, Australia (May 7 to September 6, 2020)”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Open-label and randomized parts

| Study component | Reported design |
| --- | --- |
| Part A | “open-label” |
| Part B | “randomized, double-blind, placebo-controlled” |
| Part B allocation | “3:1” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Healthy adult population

| Criterion | Reported requirement |
| --- | --- |
| Population | “healthy participants” |
| Age range | “18–55 years” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Fixed-dose titration

| Treatment component | Reported value |
| --- | --- |
| Part A dose sequence | “5, 10, and 20 mg” |
| Part A treatment duration | “12 days” |
| Initial Part B dose | “20 mg” |
| Subsequent Part B dose | “40 mg” |
| Later Part B doses | “60, 80, 100, and 120 mg” |
| Part B assessment days at later dose levels | “10, 17, 24, and 31” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using NREM Sigma-Power as a Pharmacodynamic Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Summary

NREM sigma-power was investigated as a pharmacodynamic measure of central T-type calcium-channel blockade. The study compared human changes in this signal with preclinical findings at exposures associated with tremor reduction. This is target-engagement evidence in healthy participants, not direct evidence that a specified sigma-power reduction produces a clinically meaningful benefit in essential tremor.

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-3.1.5.6.1-2"></a>

###### Frequency range used for sigma-power measurement

| Measurement | Reported frequency range |
| --- | --- |
| Absolute NREM sigma-power | “11 and 15 Hz” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Allocated participants

| Population | Reported participants |
| --- | --- |
| Part A | “N = 8” |
| Part B PRAX-944 | “N = 12” |
| Part B placebo | “N = 4” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-3.1.5.7.1-2"></a>

###### Part B pharmacodynamic analysis population

| Analysis population | PRAX-944 | Placebo |
| --- | --- | --- |
| Reported repeated-measures analysis | “N = 10” | “N = 4” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Summary

The Part B pharmacodynamic analysis used natural-log-transformed NREM sigma-power values. The repeated-measures model included timepoint, treatment, their interaction, and baseline value, with an unstructured covariance pattern. Treatment-to-placebo ratios were obtained by exponentiating the estimated between-group differences. The published analysis table included ten PRAX-944 participants and four placebo participants.

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-3.1.5.7.2-2"></a>

###### Statistical model

> “mixed model repeated measures model”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Full participant flow and reasons for exclusions from pharmacodynamic analysis

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Pharmacodynamic response in healthy participants

> “In healthy participants, sigma-power was similarly reduced by 34% to 50% at 10 to 100 mg, with no further reduction at 120 mg.”

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-3.1.5.8.3-2"></a>

###### Part B NREM sigma-power ratios versus placebo

| Assessment | Treatment-to-placebo difference ratio and 95% CI | Probability value |
| --- | --- | --- |
| Day 10, 60 mg | “0.550 (0.353, 0.859)” | “0.0132” |
| Day 17, 80 mg | “0.498 (0.257, 0.965)” | “0.0407” |
| Day 24, 100 mg | “0.482 (0.335, 0.695)” | “0.0011” |
| Day 31, 120 mg | “0.507 (0.314, 0.819)” | “0.0098” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="topic-3.1.5.8.3-3"></a>

###### Clinical efficacy in essential tremor

Not applicable.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Frequent adverse events in Part B

| Adverse event | PRAX-944 | Placebo |
| --- | --- | --- |
| Medical device site dermatitis | “25%” | “50%” |
| Headache | “16.7%” | “50%” |
| Dizziness | “25%” | “0%” |

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The study enrolled healthy adults rather than participants with essential tremor. Part A included eight participants; Part B allocated twelve to PRAX-944 and four to placebo, with ten active-treatment participants represented in the reported pharmacodynamic analysis. The treatment periods and small placebo population limit safety precision. NREM sigma-power is a target-engagement measure rather than a patient-centered clinical outcome, so these results do not establish essential tremor efficacy, a clinically meaningful response threshold, or long-term tolerability.

Source: [Scott et al. (2022)](https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28969)

## Related pages
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor.md)
- [Ulixacaltamide in Essential tremor: Terms and abbreviations](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations.md)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md)
- [Ulixacaltamide in Essential tremor: Product information and disease description](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description.md)
- [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md)
- [Ulixacaltamide in Essential tremor: References](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references.md)
- [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)
- [Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses.md)
